Literature DB >> 15093535

Oncogenic B-Raf mutations: crystal clear at last.

Amardeep S Dhillon1, Walter Kolch.   

Abstract

The Raf/MEK/ERK pathway is a conserved signaling module controlling cell growth, proliferation, apoptosis, and differentiation. Constitutive activation of this pathway is involved in malignant transformation by several oncogenes, most notably, Ras. The recent discovery by Davies et al. of somatic mutations in the B-RAF gene in human tumors has generated enormous interest in how Raf kinases are regulated and how mutations in B-RAF lead to transformation. A recent study in Cell by Wan et al. reports the crystal structure of the B-Raf kinase domain, providing important new insights into these questions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093535     DOI: 10.1016/s1535-6108(04)00087-x

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  17 in total

Review 1.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

Review 2.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

Review 3.  BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.

Authors:  Carmelo Nucera; Jack Lawler; Sareh Parangi
Journal:  Cancer Res       Date:  2011-03-29       Impact factor: 12.701

4.  Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.

Authors:  Suzanne Shelly; May B Chien; Becky Yip; Michael S Kent; Alain P Theon; Jennifer L McCallan; Cheryl A London
Journal:  Mamm Genome       Date:  2005-03       Impact factor: 2.957

5.  Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription.

Authors:  Jens Rauch; Eric O'Neill; Brigitte Mack; Christoph Matthias; Markus Munz; Walter Kolch; Olivier Gires
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

6.  BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.

Authors:  Eftychia Oikonomou; Eleni Makrodouli; Maria Evagelidou; Tobias Joyce; Lesley Probert; Alexander Pintzas
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

Review 7.  Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

Authors:  Carmelo Nucera; Melanie Goldfarb; Richard Hodin; Sareh Parangi
Journal:  Biochim Biophys Acta       Date:  2009-01-31

8.  Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors.

Authors:  Minjing Zou; Essa Y Baitei; Ali S Alzahrani; Futwan Al-Mohanna; Nadir R Farid; Brian Meyer; Yufei Shi
Journal:  Neoplasia       Date:  2009-01       Impact factor: 5.715

9.  Novel BRAF mutation in melanoma: A case report.

Authors:  Serena Trubini; Alessandro Ubiali; Carlo Terenzio Paties; Luigi Cavanna
Journal:  Mol Clin Oncol       Date:  2018-01-12

10.  14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.

Authors:  Julia Schultz; Saleh M Ibrahim; Julio Vera; Manfred Kunz
Journal:  Mol Cancer       Date:  2009-07-30       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.